PUBLICATION
Valbenazine promotes body growth via growth hormone signaling during zebrafish embryonic development
- Authors
- Su, Z., Dai, Z., Qin, F., Zhang, H., Zheng, M., Zhu, Y., Tong, Z., Weihong, S., Li, X.
- ID
- ZDB-PUB-230831-52
- Date
- 2023
- Source
- Toxicology and applied pharmacology 477: 116674 (Journal)
- Registered Authors
- Li, Xi, Su, Zhengkang, Zheng, Miaomiao, Zhu, Ya
- Keywords
- Dopamine, VBZ, VMAT2, Zebrafish larvae
- MeSH Terms
- none
- PubMed
- 37648088 Full text @ Tox. App. Pharmacol.
Citation
Su, Z., Dai, Z., Qin, F., Zhang, H., Zheng, M., Zhu, Y., Tong, Z., Weihong, S., Li, X. (2023) Valbenazine promotes body growth via growth hormone signaling during zebrafish embryonic development. Toxicology and applied pharmacology. 477:116674.
Abstract
Vesicular monoamine transporter 2 (VMAT-2) functions by uptake of cytoplasmic monoamines into vesicles for storage. Valbenazine (VBZ) is a newly FDA-approved oral VMAT-2 inhibitor used for the treatment of movement disorders such as tardive dyskinesia (TD), and Tourette syndrome (TS). Clinical data shows that VBZ is a relatively safe drug with no cardiotoxicity or hepatotoxicity. However, the effect of VBZ on embryonic development remains unknown. Here, we use zebrafish larvae as an animal model to demonstrate that VBZ exposure causes premature hatching and increases body size and hyperactivity-like behaviors in zebrafish larvae. In addition, VBZ exposure leads to increased dopamine (DA) and Glutamate (Glu) levels. Moreover, an increased in the growth hormone (gh) and enriched PI3K/AKT signaling were found in VBZ-exposed zebrafish larvae, which may explain their accelerated development. In summary, VBZ exposure may be developmentally toxic in zebrafish larvae.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping